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Angiogenesis is a complex process, requiring a finely tuned balance between numerous 
stimulatory and inhibitory signals. ALK1 is an endothelial-specific type 1 receptor of the 
TGFß receptor family. Heterozygotes with mutations in the ALK1 gene suffer from 
Hereditary Hemorrhagic Telangiectasia type 2 (HHT2). Recently, we reported that BMP9 and 
BMP10 are specific ligands for ALK1 that potently inhibit microvascular endothelial cell 
migration and growth. These data lead us to suggest that these factors might play a role in the 
control of vascular quiescence. To test this hypothesis, we checked their presence in human 
serum. We found that human serum induced Smad1/5 phosphorylation. In order to identify 
the active factor, we tested neutralizing antibodies against BMP members and found that only 
the anti-BMP9 inhibited serum-induced Smad1/5 phosphorylation. The concentration of 
circulating BMP9 was found to vary between 2 and 12 ng/ml in sera and plasma from healthy 
humans, a value well above its EC50 (50 pg/ml). These data indicated that BMP9 is circulating 
at a biologically active concentration. We then tested the effects of BMP9 in two in vivo 
angiogenic assays. We found that BMP9 strongly inhibited sprouting angiogenesis in the 
mouse sponge angiogenesis assays and that BMP9 could inhibit blood circulation in the 
chicken chorioallantoic membrane assay. Taken together, our results demonstrate that BMP9, 
circulating under a biologically active form, is a potent anti-angiogenic factor that is likely to 
play a physiological role in the control of adult blood vessel quiescence.  
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Introduction 
 
Bone morphogenetic proteins (BMPs), which belong to the TGFß superfamily, were 
originally identified as inducers of ectopic bone growth and cartilage formation. Since then, 
there has been substantial progress in our knowledge of the multiple functions of these growth 
factors1. BMPs regulate cell growth, differentiation and apoptosis of various cell types, and 
they are critically important in the morphogenesis and differentiation of tissues and organs. 
BMP9, also known as GDF2, is expressed in the adult liver by non-parenchymal cells (i.e. 
endothelial, stellate, and Kupffer cells)2 and in the septum and spinal cord of mouse 
embryos3. BMP9 has been described as a hematopoietic, hepatogenic, osteogenic and 
chondrogenic factor. It has also been identified as a regulator of glucose metabolism, capable 
of reducing glycaemia in diabetic mice and as a differentiation factor for cholinergic neurons 
in the central nervous system3. More recently, it was shown to induce the expression of 
hepcidin, an hormone that plays a key role in iron homeostasis4.  
ALK1 (activin receptor like-kinase 1) is an endothelial-specific type I receptor of the 
TGFß receptor family that is implicated in the pathogenesis of Hereditary Hemorrhagic 
Telangiectasia type 2 (HHT2) also known as the Rendu-Osler disease type 2 (RO2)5. The 
disease is an autosomal dominant vascular disorder characterized by recurrent nosebleeds, 
cutaneous telangiectases, and arteriovenous malformations in the lungs, brain, liver and 
gastrointestinal tract6. The majority of cases are caused by mutations in either endoglin (ENG) 
or ALK1 (ACVRL1) genes, thus defining HHT1 and HHT2, respectively. Mutations in 
SMAD4 are seen in patients with the combined syndrome of Juvenile Polyposis (JP) and HHT 
(JP-HHT)7. Despite the identification of these mutations as the causative factor in HHT, the 
mechanism by which these mutations cause the HHT phenotype remain unclear. 
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ALK1 is one of seven known type I receptors for TGF-ß family members8. Signaling 
through the TGFß receptor family occurs via ligand binding to heteromeric complexes of type 
I and type II serine/threonine kinase receptors
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9. The type I receptor determines signal 
specificity in the receptor complexes. Activation of ALK1 induces phosphorylation of 
receptor-regulated Smad1, 5 and 810, which assemble into heteromeric complexes with the 
common partner Smad4. These heteromeric complexes translocate to the nucleus, where they 
regulate the transcription of target genes. 
 ALK1 has long been known as an orphan type I receptor of the TGFß family 
predominantly present on endothelial cells. Subsequently, TGFß1 and 3, primarily known as 
ligands for ALK5, were also shown to bind ALK1, albeit only in the presence of ALK511. In 
2005, a publication describing the crystal structure of BMP9 reported that BMP9 specifically 
binds biosensor-immobilized recombinant ALK1 and BMPRII extracellular domains12. More 
recently, we demonstrated that BMP9 and BMP10 are potent ligands for ALK1 on human 
dermal microvascular endothelial cells13 and this was since confirmed by another group14. 
BMP9 is very potent (EC50 = 2 pM) and, in contrast to TGFß1 or 3
11,  induces a very stable 
Smad1/5/8 phosphorylation over time13. Interestingly, another ALK1 ligand, distinct from 
TGFß1 and TGFß3 and that could signal in the absence of ALK5 or TGFßRII, had been 
previously described in human serum, but not identified15. The aim of the present work was to 
identify this circulating ALK1 ligand. Here we demonstrate that BMP9 is indeed the ALK1 
ligand present in human serum. BMP9 circulates in a biologically active form at a 
concentration of 2-12 ng/ml. Furthermore, we report that BMP9 is a potent inhibitor of 
angiogenesis and a regulator of vascular tone. 
 
Materials and Methods 
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An expanded materials and methods is available in the online data supplement at 1 
http://www.circresaha.org. 2 
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DNA transfection and dual luciferase activity assay 
NIH-3T3 cells were transfected as previously described13. Firefly and renilla luciferase 
activities were measured sequentially with the Dual-Luciferase reporter assay (Promega). 
Results are expressed as ratios of firefly luciferase activity over renilla luciferase activity. 
(See the online data supplement). 
Purification of the ALK1 ligand from human serum 
250 ml of human serum (pool of human sera from about 250 different individuals, Cambrex) 
were diluted with 250 ml PBS (Phosphate Buffer Saline 0.15 M, pH 7.4) and purified through 
five different steps as detailed in the online data supplement.  
Western blot analysis  
Western blots were performed as previously described13. (See the online data supplement). 
Blood donors 
Between December 2006 and July 2007, blood samples (7 ml) were taken from 20 patients (8 
women, 12 men, mean age of 44 ± 12 years) with clinical features of HHT (13 with ACVRL1 
mutations, 2 with ENG mutations and 5 with unidentified mutations) and 20 healthy 
volunteers (8 women, 12 men, mean age of 44 ± 10 years) from which serum or plasma (K3E 
tubes, Becton Dickinson, Pont de Claix, France) were obtained. Serum and plasma aliquots 
were frozen at -20°C. Informed consent was obtained from all blood donors. The 
investigation conformed to the principles outlined in the Helsinki declaration. The donors 
were randomly assigned a number. Patients were considered to be affected by HHT if they 
had at least three out of the four Curaçao consensus criteria16: epistaxis, telangiectases, 
visceral lesions and family history of HHT disease.  
Chorioallantoic Membrane (CAM) Assay 
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The effect of BMP9 on vascularization in the chick chorionallantoic membrane was studied as 
described in the online data supplement. 
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Mouse subcutaneous sponge angiogenesis assay 
The effect of BMP9 on neovascularization in the mouse sponge assay in response to FGF-2 
was studied as described in the online data supplement. 
Statistics  
Statistical analysis was performed using a Mann Whitney test (**: p < 0.01; *: p < 0.05).  
 
Results  
 
Presence of an ALK1 ligand in human serum that differs from TGFβ 
The luciferase reporter construct  (BRE, BMP Responsive Element) which contains repeated 
sequences from the Id1 promoter has been developed to specifically measure activation of the 
Smad1/5/8 pathway17. This plasmid, together with an ALK1-expression plasmid, were 
transfected in NIH-3T3 cells in order to check for the presence of an ALK1 ligand in human 
serum. Treatment of these cells with 2% human serum strongly stimulated luciferase activity 
(9 fold, Fig. 1A). In order to determine whether this activity was due to TGFß, a pan-specific 
TGFß neutralizing antibody was added to serum. As shown in Figure 1A, addition of the 
neutralizing antibody did not affect serum activity. Furthermore, the addition of recombinant 
TGFß1 (0.5 ng/ml) did not activate this reporter gene and actually decreased basal luciferase 
expression (Fig. 1A). Heat-treatment, in order to activate the latent TGFß present in serum, 
did not result in BRE activation (Fig. 1A). We next examined whether human serum could 
activate the CAGA promoter, which is known to be specifically activated by the Smad2/3 
pathway in response to TGFß. We found that human serum caused a small induction of the 
CAGA promoter (4 fold), while heat-treated serum and recombinant TGFß1 strongly 
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activated it (17 and 42 fold, respectively, Fig. 1B). These activations were inhibited by the 
addition of the pan-specific TGFß neutralizing antibody (Fig. 1B). The BRE promoter is 
specific for the Smad1/5/8 pathway and therefore can be activated by all the type I receptors 
known to phosphorylate these Smads, namely ALK1, ALK2, ALK3 and ALK6.  Therefore, in 
order to confirm that the activation of BRE by human serum was actually due to ALK1 
activation, we tested the ability of the recombinant extracellular domains of these receptors to 
interfere with the human serum response. As shown in Fig. 1C, addition of ALK1ecd very 
strongly inhibited the human serum response. ALK3ecd and ALK6ecd only slightly inhibited 
this response while ALK2ecd had no effect.  Interestingly, we could also demonstrate that 
soluble endoglin inhibited this biological response (Fig.1C). Taken together, these findings 
demonstrate that an ALK1-stimulating ligand, distinct from TGFß1, 2 or 3 is present in 
human serum.  
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Purification and molecular weight estimation of the ALK1 ligand from human serum 
We next attempted to purify the activating factor from human serum.  The factor was purified 
approximately 100 fold from 250 ml of human serum, following the purification scheme 
shown in Fig. 2A. After five purification steps, the fractions eluting from the Pro-RPC 
column were analyzed by SDS-PAGE under non-reducing conditions. The gel lanes 
containing the active fractions (23 and 24) were then cut into 6 bands and the proteins in each 
band were electroeluted, renatured and tested for ALK1-stimulating activity. The activity was 
detected in band 5 which corresponded to an apparent molecular weight comprised between 
17 and 28 kDa (Fig. 2B).  
The ALK1 activity of the human serum is due to BMP9 
In a recent work, we have demonstrated that BMP9 is an activating ligand for ALK113 and 
this was since confirmed by another group14. As the apparent molecular weight of the ALK1-
stimulating activity present in human serum appears to lie between 17 and 28 kDa, we 
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hypothesized that this activity could be due to circulating BMP9 (MW 22 kDa). To test this 
hypothesis, we utilized a BMP9 neutralizing antibody. This antibody was highly specific as it 
completely abolished the BRE-luciferase response to BMP9 while it had no effect on the 
BMP10-induced response (BMP10 has the highest sequence homology with BMP9), or on the 
BMP2-induced response (Fig. 3A). We then tested this antibody on the ALK1-stimulating 
activity in serum and observed nearly complete inhibition of BRE-stimulating activity (Fig. 
3B). This was also the case for the purified active fractions (fractions 23 and 24 from Fig. 2A) 
from human serum (Fig. 3B). To further confirm that BMP9 is the only active circulating 
member of the TGFß family present in serum capable of activating the BRE promoter in 
ALK1-expressing NIH-3T3 cells, we tested neutralizing antibodies for other BMPs. 
Neutralizing BMP2/4 and BMP7 antibodies had no effect on human serum activity (Fig. 3C) 
while both inhibited the BRE response to either recombinant BMP2 or BMP7 (Fig. 3D). We 
also evaluated whether the circulating BMP antagonist noggin inhibits human serum ALK1-
stimulating activity. We observed that the addition of noggin did not inhibit the ALK1-
stimulating activity from human serum (Fig. 3C) while it inhibited BMP2 or BMP7 activity 
(Fig. 3D). We could also demonstrate for the first time that noggin did not inhibit the 
induction of BRE activity by recombinant BMP9 (Fig. 3D). Finally, we tested the effects of 
the neutralizing BMP9 antibody on serum activation of Smad1/5 phosphorylation in human 
microvascular endothelial cells (HMVEC-d). As shown in Figure 3E, human serum induced 
rapid and strong Smad1/5 phosphorylation, that could be inhibited in a dose-dependent 
manner by the addition of neutralizing anti-BMP9 antibody or by the addition of ALK1ecd. 
Taken together these data lead to the conclusion that the ALK1-stimulating activity of human 
serum is due to BMP9. 
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Having demonstrated that BMP9 is present in human serum, we also evaluated its presence in 
human plasma. We measured BMP9 levels in the sera and the plasma of four healthy 
individuals and found similar levels of BRE activity in both biological fluids (Fig. 4A). Using 
the BRE luciferase reporter assay and recombinant mature BMP9 (R&D Systems) as a 
standard for calibration, we determined that the BMP9 concentration in a pool of human sera 
was 7.5 ± 0.6 ng/ml (Fig. 4B). BMP9 binds ALK1 and endoglin
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13, two receptors whose genes 
are mutated in HHT. This prompted us to evaluate the serum levels of BMP9 in HHT patients 
versus a normal population.  Twenty patients with clinical features of HHT were enrolled in 
this study. The two populations were matched for gender ratio (8 were female and 12 were 
male) and age (mean = 44 years). The study of BMP9 levels in the healthy population 
demonstrated a mean level of circulating BMP9 very close to the one found in the pooled 
human sera (6.2 ± 0.6 ng/ml) with a range of variation between 2 and 12 ng/ml (Fig. 4C). As 
shown in Fig. 4C, no statistically significant difference in the serum level of BMP9 could be 
detected between healthy humans and HHT patients (6.2 ± 0.6 ng/ml versus 5.0 ± 0.7 ng/ml, 
respectively, n = 20). Similar data were obtained using plasma (data not shown). Sera that had 
high levels of BMP9 (above 8 ng/ml) were tested again in the presence of the neutralizing 
anti-BMP9 antibody in order to confirm that all this activity was due to BMP9. The antibody 
totally neutralized the activity in all samples (data not shown).  
BMP9 is a potent inhibitor of angiogenesis in vivo 
We and others have previously demonstrated that BMP9 inhibits endothelial cell migration 
and proliferation13,14. In addition, it was further demonstrated that BMP9 inhibited ex vivo 
endothelial cell sprouting from metatarsals14. Similarly, we were able to show that BMP9 
inhibited endothelial sprouting from embryoid bodies derived of embryonic stem cells 
committed to endothelial differentiation (supl. Fig. 1). Taken together these data, suggest that 
BMP9 might act as an inhibitor of angiogenesis. To further characterize the anti-angiogenic 
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activity of BMP9, we tested its effect in two in vivo angiogenic assays. First, we assessed the 
effect of BMP9 in the mouse subcutaneous sponge assay. In this study, Balb-C mice received 
under the dorsal skin a cellulose sponge hydrated with FGF-2 or FGF-2 and BMP9. Factors 
were re-injected into the sponge on day 1, 2 and 4 as described in Materials and Methods. The 
angiogenic response was then assessed on day 7. As shown in Figure 5, BMP9 treatment 
clearly inhibited the angiogenic response. This inhibitory effect could be quantitated by 
measuring the hemoglobin content of the sponges (Fig. 5B, 1.23 ± 0.22 mg with FGF-2 
versus 0.54 ± 0.06 mg with FGF-2 and BMP9, p<0.05). We then looked whether BMP9 
addition would also lead to destabilization of already formed vessels. To do this, Balb-C mice 
received a cellulose sponge hydrated with FGF-2, which was re-injected into the sponge on 
days 1 and 2. Angiogenesis, as measured by hemoglobin levels, was already strong by day 4 
(data not shown). BMP9 was then added on day 4, 5 and 6 and the angiogenic response was 
assessed on day 7. Interestingly, we found that BMP9 added after the initiation of 
angiogenesis by FGF-2 still significantly inhibited this process (Fig. 5C).  
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We also tested the effect of BMP9 in the chick chorioallantoic membrane (CAM) assay that 
allows to study fetal neoangiogenesis. BMP9 or the vehicle (PBS, BSA 0.1%) was applied for 
24h side by side onto the same CAM on day 9 of embryo development (Fig. 6). Four doses of 
BMP9 were tested (5.5, 27.5, 55 and 550 ng). BMP9 treatment impaired in a dose-dependent 
manner CAM angiogenesis as seen on photographs (Fig. 6B); this effect was further 
confirmed by FITC-Dextan injection (fig. 6C): at low dose (5.5 ng) BMP9 had minimal effect 
on the vasculature, at 27.5 ng only the small vessels were affected, and at 55 ng a complete 
disappearance of all the vessels is induced. A higher dose of BMP9 (550 ng) produced chick 
embryo death 4 to 6 h following its addition (data not shown). Serial cross sections of the 
CAM, stained either with hematoxylin/eosin, isolectin (endothelial cells) or anti-α smooth 
muscle actin (pericytes), show that this effect of BMP9 was not due to vascular pruning as the 
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number of vessels was not modified (supl Fig. 2A). These results suggested that vessels were 
still present but not functional. Indeed, when we follow the effect of BMP9 (550 ng) at earlier 
time-points, we could observe constrictions and/or thrombosis of some vessels suggesting that 
BMP9 might regulate vascular tone (supl Fig. 2B). These irregularities in vessel diameter are 
also observed on CAM cross section after a 24h treatment with BMP9 (55 ng) visualized after 
hematoxylin/eosin labeling (supl Fig. 2C).  
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Discussion 
 
Angiogenesis is a complex process, requiring a finely tuned balance between 
numerous stimulatory and inhibitory signals. In adulthood most blood vessels remain 
quiescent and angiogenesis occurs only in the cycling ovary, in the endometrium and in the 
placenta during pregnancy, and during wound healing18. This implicates that circulating 
quiescence factors must exist in blood. It was previously published that human serum is able 
to specifically activate the Smad1/5 pathway, suggesting the presence of active BMPs in 
blood15. We here report that the Smad1/5-stimulating activity present in human serum is due 
to biologically active BMP9. Furthermore, we demonstrate using two in vivo angiogenic 
assays that BMP9 is a potent inhibitor of angiogenesis. These data lead us to propose that the 
circulating anti-angiogenic BMP9 could play a role as a regulator of endothelial quiescence.  
We found that BMP9 was present at similar levels in both human serum and plasma, 
suggesting that circulating BMP9 is derived from plasma rather than from platelets. The 
circulating concentration of BMP9 is between 2 and 12 ng/ml, as determined with the BRE 
reporter gene assay using recombinant mature BMP9 as a standard, is between 2 and 12 
ng/ml. This concentration is well above its EC50 (50 pg/ml, 2 pM), previously determined in 
microvascular endothelial cells13. In the present work, we showed that human serum activity 
could be inhibited by neutralizing BMP9 antibodies and by ALK1 extracellular domain, 
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confirming that this activity is due to a factor that can bind ALK1. We have previously shown 
that both BMP9 and BMP10 bind to ALK1
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13. However, we here demonstrate that the 
biological ALK1-stimulating activity in human serum is exclusively due to BMP9 and not to 
BMP10. The absence of BMP10 in blood is likely due to the pattern of BMP10 expression 
that appears to be restricted to the developing and postnatal heart19. In contrast, BMP9 
expression is high in both embryonic and adult liver2, suggesting that this is the likely source 
of circulating protein. Other TGFß family members known to activate the Smad1/5 pathway 
have been previously described in serum or plasma, specifically BMP7 and BMP420, 21. 
However, their concentrations are lower (100-400 pg/ml) and their receptor affinities are also 
much lower (in the nM range) than the affinity of BMP9 for ALK1 (in the pM range), 
suggesting that they are not circulating at biologically active levels. Furthermore, these factors 
appear to circulate as inactive complexes associated with antagonists such as noggin22. In 
contrast, we found that noggin does not inhibit BMP9- or human serum-induced BRE activity 
(Fig. 3C and D). This might be another reason why BMP9 is the only active circulating BMP 
in healthy human serum under our biological conditions.  
HHT is a dominantly inherited genetic disorder (mutations of ACVRL1 or ENG), and 
haploinsufficiency (reduced amount of functional protein) is likely to be the cause of 
associated vessel malformations. One could imagine that the organism could compensate this 
haploinsufficiency by increasing the synthesis of the receptor ligand. However, we observed 
no significant difference between the serum BMP9 levels of healthy humans and HHT 
patients, suggesting that there is no compensation by increased BMP9 in this disease.  
BMP9 has been previously shown to be a potent regulator of osteogenesis, 
chondrogenesis, glucose metabolism, iron homeostasis4 and a differentiation factor for 
cholinergic neurons3. In a recent study, we demonstrated that BMP9 is also a potent inhibitor 
of endothelial cell proliferation and migration13. This was since confirmed by another group 
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who further demonstrated that BMP9 inhibited ex vivo endothelial cell sprouting from 
metatarsals
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14. In the present work, we confirmed this data in another ex vivo endothelial cell 
sprouting assay and further demonstrated that BMP9 is an important in vivo regulator of 
angiogenesis. Using the mouse sponge assay, we could show that BMP9 inhibited 
neoangiogenesis in response to FGF-2 but also induced destabilization of already formed 
vessels (Fig. 5B and C). This latter point suggests that BMP9 could be a useful tool to target 
tumor angiogenesis. Using the CAM assay, we found that BMP9 treatment inhibited blood 
circulation in a dose-dependent manner (Fig. 6).  This was not due to a decrease in vessel 
number but rather to vasoconstrictions and/or thrombosis. This point is interesting as BMP9 
signals through BMPRII and that mutations in BMPR2 have been found responsible for 
familial pulmonary hypertension23. These data represent the first demonstration of in vivo 
effects of BMP9 on angiogenesis. As BMP9 is circulating under a biologically active form in 
adults, our data prompt us to suggest that BMP9 may be a systemic inhibitor of angiogenesis 
and a regulator of vascular tone. These data are supported by previous work demonstrating 
that phosphorylated Smad1, Smad5 and/or Smad8 are detectable in mouse aorta 
cryosections24 indicating that, in vivo, these cells constantly receive stimulation by BMPs. 
The role of BMP family members on vascular development has not been extensively studied. 
Data are not clear and often show paradoxical effects between in vitro and in vivo assays. 
GDF5/BMP14 was one of the first BMPs described for its pro-angiogenic activity in vivo25. 
BMP2 was shown to increase angiogenesis in the sponge assay and to induce 
neovascularization of developing tumors26 while it had no effect in the CAM assay25. Overall, 
in vivo data seem to indicate that BMPs acting through ALK3/ALK6 receptors are pro-
angiogenic. Our data demonstrate that, in contrast to these BMPs, BMP9 inhibits 
angiogenesis via ALK1. This clearly separates BMPs into two categories: the pro-angiogenic 
BMPs that transduce via ALK3/6 and the anti-angiogenic BMPs (BMP9) that transduce via 
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ALK1.  Since all of these BMPs activate the Smad1/5 pathway, it is unlikely that this pathway 
represents the only signaling pathway implicated in these mechanisms. This is highly 
consistent with our previous work demonstrating that ALK1-mediated inhibition of 
endothelial proliferation and migration is Smad-independent
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
27. In accordance with these data, 
it has recently been described that ALK1 directly phosphorylates endoglin, resulting in 
inhibition of endothelial cell proliferation28. BMP9 was also recently reported to inhibit Akt 
phosphorylation, which is clearly implicated in the migration of endothelial cells29. The 
presence of both positive and negative BMP-mediated signaling responses in endothelial cells 
may provide a useful paradigm for the further dissection of the mechanisms by which BMPs 
participate in the control of angiogenesis. 
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Figure 1. Presence of an ALK1 ligand in human serum that differs from TGFβ 
NIH-3T3 cells were transiently transfected with pALK1 and pRL-TK-luc and either 
pGL3(BRE)-luc (A) or pGL3(CAGA)12-luc (B). Transfected cells were then treated either 
with human serum (2%), TGFß1 (0.5 ng/ml) or heat-activated human serum (2%) with or 
without pan-specific neutralizing TGFß antibody (1 µg/ml). C: NIH-3T3 cells were 
transiently transfected with pGL3(BRE)-luc, pALK1 and pRL-TK-luc. Transfected cells were 
then treated with human serum (2%) in presence or absence of either ALK1ecd, ALK2ecd, 
ALK3ecd, ALK6ecd or soluble endoglin (200 ng/ml). The luciferase activities were then 
measured as described in Materials and Methods. Data shown in A, B and C are expressed as 
mean values ± SD from a representative experiment out of three.  
Figure 2. Purification and estimation of the molecular weight of the ALK1 ligand from 
the human serum 
A: Scheme of purification of ALK1 ligand from 250 ml of a pool of human sera. The proteins 
present in the active fractions (23 and 24) of the Pro-RPC column and the two surrounding 
fractions (22 and 25), as determined with the BRE reporter gene assay (see Material and 
Methods), were then separated by 12% SDS-PAGE. After the migration, the gel (fractions 23 
and 24) was sliced into 6 parts as indicated by the dotted lines and the proteins were electro-
eluted. B: NIH-3T3 cells were transiently transfected with pGL3(BRE)-luc, pALK1 and pRL-
TK-luc. Transfected cells were then treated with 100 µl of either the active fractions (fraction 
23 and 24) or 100 µl of the proteins eluted from each gel slice. The luciferase activities were 
then measured as described in Materials and Methods. Data are expressed as mean values ± 
SD from a representative experiment out of three.  
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Figure 3. The ALK1 activity of the human serum is due to BMP9 1 
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A, B, C and D: NIH-3T3 cells were transiently transfected with pGL3(BRE)-luc, pRL-TK-luc 
and pALK1. A: Transfected cells were then treated with BMP9 (0.1 ng/ml), or BMP10 (20 
ng/ml), or BMP2 (100 ng/ml) in the presence or the absence of a neutralizing BMP9 antibody 
(1 µg/ml) or an isotype-matched control antibody (1µg/ml) . B: Transfected cells were then 
treated with human serum (1%) or 100 µl of active fraction (fractions 23 and 24 of Fig. 2A). 
C: Transfected cells were treated with 2% human serum in the presence or the absence of 
neutralizing antibodies (anti-BMP9 (2 µg/ml), anti-BMP2/4 (10 µg/ml), or anti-BMP7 (10 
µg/ml)) or with recombinant noggin (1 µg/ml). D: Transfected cells were treated with either 
BMP9 (0.05 ng/ml), BMP2 (50 ng/ml) or BMP7 (100 ng/ml) in the presence or the absence of 
neutralizing antibodies (anti-BMP9 (2 µg/ml), anti-BMP2/4 (10 µg/ml), or anti-BMP7 (10 
µg/ml)) or with recombinant noggin (1 µg/ml). The luciferase activities were then measured as 
described in Materials and Methods. Data shown in A, B, C and D are expressed as mean 
values ± SD from a representative experiment out of three. E: HMVEC-d were serum-starved 
for 1 h and were then treated with 2% human serum for 1 h in the presence or absence of 
neutralizing BMP9 antibody (1 or 10 µg/ml) or ALK1ecd (100 ng/ml). Cell lysates (20 µg 
proteins) were resolved by 10% SDS-PAGE, and immunoblotted with antibodies against 
phosphoSmad1/5/8 or against α-tubulin.  
Figure 4. Determination of BMP9 concentration in human serum 
A: NIH-3T3 cells were transiently transfected with pGL3(BRE)-luc, pRL-TK-luc, pALK1. 
Transfected cells were treated with 0.5% of human serum or plasma of 4 different healthy 
donors. B: linear regression for the determination of BMP9 serum concentration. NIH-3T3 
cells were transiently transfected with pGL3(BRE)-luc, pRL-TK-luc, pALK1. Transfected 
cells were then treated with 0.1 or 0.3% of a pool of human sera. The luciferase activities 
were then measured as described in Materials and Methods. Data shown in A and B are 
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expressed as mean values ± SD from a representative experiment out of three. C: BMP9 
serum levels measured in 20 patients with HHT and 20 healthy donors. The line indicates the 
mean value. The difference was not statistically significant.  
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Figure 5. Effect of BMP9 on angiogenesis in the mice sponge assay 
A and B: Bal-C mice received a subcutaneous cellulose sponge treated with FGF-2 (200 ng) 
and/or BMP9 (20 ng) under the dorsal skin. Injections in the sponge of FGF-2 and/or BMP9 
diluted in PBS were performed on day 1 and day 2 and a last injection was performed on day 
4 with BMP9 alone. C: Bal-C mice received a subcutaneous cellulose sponge treated with 
FGF-2 (200 ng) diluted in PBS under the dorsal skin. Injections of FGF-2 were performed on 
day 1 and day 2. BMP9 (20 ng) or PBS were injected on day 4, 5 and 6. Animals were 
sacrificed on day 7 and the sponges were photographed (A). Hemoglobin content was 
measured in 1 ml of RIPA buffer extract of the sponge and adjacent vascular network (B and 
C). B: Data are expressed as mean values ± SEM from a representative experiment (five mice 
in each groups) out of three. C: Data are expressed as mean values ± SEM of two experiments 
(nine mice in each groups). (* p < 0.05; ** p < 0.01). 
 
Figure 6. Effect of BMP9 on vessel formation in the chick chorioallantoic membrane 
assay 
On day 9, the CAM received either 25 µl of BMP9 (5.5 ng, 27.5 ng, 55 ng or 550 ng) or 
vehicle (Control).  The photographs shown were taken before (T 0h) and after treatment (T 
24h) and are representative of the results obtained in an additional five eggs per group. Low 
magnification pictures of CAMs at T 0h(A) and T 24h (B); C: 24 h after treatment, FITC 
dextran was injected in the CAM vessels, fluorescent images. Arrow indicates a vessel that is 
not affected by BMP9 treatment; arrowhead indicates a vessel that cannot be seen after BMP9 
treatment.  
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